Table 1.
Clinical characteristics of the participants (n = 129).
| Sex | ||
| Male, n (%) | 18 | (14.0) |
| Female, n (%) | 111 | (86.0) |
| Age (years) | 58 | (21–91) |
| Body weight (kg) | 55.0 | (38.0–88.7) |
| Liver function test values (before prescription of TJ-125) | ||
| AST (IU/L) | 20 | (11–74) |
| ALT (IU/L) | 15 | (5–101) |
| ALP (IU/L) | 208 | (80–473) |
| γ-GTP (IU/L) | 18 | (8–190) |
| T-Bill (mg/dL) | 0.6 | (0.2–2.0) |
| Alb (g/dL) | 4.3 | (2.4–5.3) |
| Dosing period (days) | 151 | (14–1404) |
| Concurrent Kampo medicines (n) | 1 | (0–3) |
| Daily intake of cinnamon bark contained in Kampo medicines (g/day) | 5.0 | (4.0–16.0) |
| Daily intake of coumarin (mg/kg/day) | 0.113 | (0.049–0.541) |
| More than the TDI of coumarin, n (%) | 98 | (76.0) |
| Incidence of abnormal change in liver function test values, n (%) | 23 | (17.8) |
Variables expressed as median (range).